Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

Patrick Van Dijck; Jelmer  Sjollema; Bruno P.A.  Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R. Andes; Maiken C. Arendrup; Axel A. Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E.  Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G. Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M. Johnson; Shawn R. Lockhart; José L. López-Ribot; Johan Maertens; Carol A. Munro; Jeniel E. Nett; Clarissa J. Nobile; Michael A. Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E. Verweij; Adilia Warris; Joost Wauters; Michael R. Yeaman; Sebastian A.J. Zaat; Karin Thevissen

doi:10.15698/mic2018.07.638

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

Patrick Van Dijck, Jelmer Sjollema, Bruno P.A. Cammue, Katrien Lagrou, Judith Berman, Christophe d'Enfert, David R. Andes, Maiken C. Arendrup, Axel A. Brakhage, Richard Calderone, Emilia Cantón, Tom Coenye, Paul Cos, Leah E. Cowen, Mira Edgerton, Ana Espinel-Ingroff, Scott G. Filler, Mahmoud Ghannoum, Neil A R Gow, Hubertus HaasMary Ann Jabra-Rizk, Elizabeth M. Johnson, Shawn R. Lockhart, José L. López-Ribot, Johan Maertens, Carol A. Munro, Jeniel E. Nett, Clarissa J. Nobile, Michael A. Pfaller, Gordon Ramage, Dominique Sanglard, Maurizio Sanguinetti, Isabel Spriet, Paul E. Verweij, Adilia Warris, Joost Wauters, Michael R. Yeaman, Sebastian A.J. Zaat, Karin Thevissen

Research output: Contribution to journal › Review article › peer-review

79 Citations (Scopus)

10 Downloads (Pure)

Abstract

Unlike superficial fungal infections of the skin and nails, which are the most common fungal diseases in humans, invasive fungal infections carry high morbidity and mortality, particularly those associated with biofilm formation on indwelling medical devices. Therapeutic management of these complex diseases is often complicated by the rise in resistance to the commonly used antifungal agents. Therefore, the availability of accurate susceptibility testing methods for determining antifungal resistance, as well as discovery of novel antifungal and antibiofilm agents, are key priorities in medical mycology research. To direct advancements in this field, here we present an overview of the methods currently available for determining (i) the susceptibility or resistance of fungal isolates or biofilms to antifungal or antibiofilm compounds and compound combinations; (ii) the in vivo efficacy of antifungal and antibiofilm compounds and compound combinations; and (iii) the in vitro and in vivo performance of anti-infective coatings and materials to prevent fungal biofilm-based infections.

Original language	English
Pages (from-to)	300-326
Number of pages	27
Journal	Microbial Cell
Volume	5
Issue number	7
Early online date	14 Jun 2018
DOIs	https://doi.org/10.15698/mic2018.07.638
Publication status	Published - Jul 2018

Bibliographical note

KT acknowledges receipt of a mandate of Industrial Research Fund (IOFm/05/022). JB acknowledges funding from the European Research Council Advanced Award 3400867/RAPLODAPT and the Israel Science Foundation grant # 314/13 (www.isf.il). NG acknowledges the Wellcome Trust and MRC for funding. CD acknowledges funding from the Agence Nationale de Recherche (ANR-10-LABX-62-IBEID). CJN acknowledges funding from the National Institutes of Health R35GM124594 and R21AI125801. AW is supported by the Wellcome Trust Strategic Award (grant 097377), the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen MaCA: outside this study MaCA has received personal speaker’s honoraria the past five years from Astellas, Basilea, Gilead, MSD, Pfizer, T2Candida, and Novartis. She has received research grants and contract work paid to the Statens Serum Institute from Astellas, Basilea, Gilead, MSD, NovaBiotics, Pfizer, T2Biosystems, F2G, Cidara, and Amplyx. CAM acknowledges the Wellcome Trust and the MRC MR/N006364/1. PVD, TC and KT acknowledge the FWO research community: Biology and ecology of bacterial and fungal biofilms in humans (FWO WO.009.16N). AAB acknowledges the Deutsche Forschungsgemeinschaft – CRC FungiNet.

Keywords

antifungal susceptibility testing
biofilm inhibition
biofilm eradication
antibiofilm material coating
in vivo models

Access to Document

10.15698/mic2018.07.638Licence: CC BY

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms
© 2018 Van Dijck et al. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged. https://creativecommons.org/licenses/by/4.0/
Final published version, 948 KBLicence: CC BY

Cite this

Dijck, P. V., Sjollema, J., Cammue, B. P. A., Lagrou, K., Berman, J., d'Enfert, C., Andes, D. R., Arendrup, M. C., Brakhage, A. A., Calderone, R., Cantón, E., Coenye, T., Cos, P., Cowen, L. E., Edgerton, M., Espinel-Ingroff, A., Filler, S. G., Ghannoum, M., Gow, N. A. R., ... Thevissen, K. (2018). Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 5(7), 300-326. https://doi.org/10.15698/mic2018.07.638

Dijck, PV, Sjollema, J, Cammue, BPA, Lagrou, K, Berman, J, d'Enfert, C, Andes, DR, Arendrup, MC, Brakhage, AA, Calderone, R, Cantón, E, Coenye, T, Cos, P, Cowen, LE, Edgerton, M, Espinel-Ingroff, A, Filler, SG, Ghannoum, M, Gow, NAR, Haas, H, Jabra-Rizk, MA, Johnson, EM, Lockhart, SR, López-Ribot, JL, Maertens, J, Munro, CA, Nett, JE, Nobile, CJ, Pfaller, MA, Ramage, G, Sanglard, D, Sanguinetti, M, Spriet, I, Verweij, PE, Warris, A, Wauters, J, Yeaman, MR, Zaat, SAJ & Thevissen, K 2018, 'Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms', Microbial Cell, vol. 5, no. 7, pp. 300-326. https://doi.org/10.15698/mic2018.07.638

@article{9c99147444cf404d962d6156c6450e35,

title = "Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms",

abstract = "Unlike superficial fungal infections of the skin and nails, which are the most common fungal diseases in humans, invasive fungal infections carry high morbidity and mortality, particularly those associated with biofilm formation on indwelling medical devices. Therapeutic management of these complex diseases is often complicated by the rise in resistance to the commonly used antifungal agents. Therefore, the availability of accurate susceptibility testing methods for determining antifungal resistance, as well as discovery of novel antifungal and antibiofilm agents, are key priorities in medical mycology research. To direct advancements in this field, here we present an overview of the methods currently available for determining (i) the susceptibility or resistance of fungal isolates or biofilms to antifungal or antibiofilm compounds and compound combinations; (ii) the in vivo efficacy of antifungal and antibiofilm compounds and compound combinations; and (iii) the in vitro and in vivo performance of anti-infective coatings and materials to prevent fungal biofilm-based infections.",

keywords = "antifungal susceptibility testing, biofilm inhibition, biofilm eradication, antibiofilm material coating, in vivo models",

author = "Dijck, {Patrick Van} and Jelmer Sjollema and Cammue, {Bruno P.A.} and Katrien Lagrou and Judith Berman and Christophe d'Enfert and Andes, {David R.} and Arendrup, {Maiken C.} and Brakhage, {Axel A.} and Richard Calderone and Emilia Cant{\'o}n and Tom Coenye and Paul Cos and Cowen, {Leah E.} and Mira Edgerton and Ana Espinel-Ingroff and Filler, {Scott G.} and Mahmoud Ghannoum and Gow, {Neil A R} and Hubertus Haas and Jabra-Rizk, {Mary Ann} and Johnson, {Elizabeth M.} and Lockhart, {Shawn R.} and L{\'o}pez-Ribot, {Jos{\'e} L.} and Johan Maertens and Munro, {Carol A.} and Nett, {Jeniel E.} and Nobile, {Clarissa J.} and Pfaller, {Michael A.} and Gordon Ramage and Dominique Sanglard and Maurizio Sanguinetti and Isabel Spriet and Verweij, {Paul E.} and Adilia Warris and Joost Wauters and Yeaman, {Michael R.} and Zaat, {Sebastian A.J.} and Karin Thevissen",

note = "KT acknowledges receipt of a mandate of Industrial Research Fund (IOFm/05/022). JB acknowledges funding from the European Research Council Advanced Award 3400867/RAPLODAPT and the Israel Science Foundation grant # 314/13 (www.isf.il). NG acknowledges the Wellcome Trust and MRC for funding. CD acknowledges funding from the Agence Nationale de Recherche (ANR-10-LABX-62-IBEID). CJN acknowledges funding from the National Institutes of Health R35GM124594 and R21AI125801. AW is supported by the Wellcome Trust Strategic Award (grant 097377), the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen MaCA: outside this study MaCA has received personal speaker{\textquoteright}s honoraria the past five years from Astellas, Basilea, Gilead, MSD, Pfizer, T2Candida, and Novartis. She has received research grants and contract work paid to the Statens Serum Institute from Astellas, Basilea, Gilead, MSD, NovaBiotics, Pfizer, T2Biosystems, F2G, Cidara, and Amplyx. CAM acknowledges the Wellcome Trust and the MRC MR/N006364/1. PVD, TC and KT acknowledge the FWO research community: Biology and ecology of bacterial and fungal biofilms in humans (FWO WO.009.16N). AAB acknowledges the Deutsche Forschungsgemeinschaft – CRC FungiNet.",

year = "2018",

month = jul,

doi = "10.15698/mic2018.07.638",

language = "English",

volume = "5",

pages = "300--326",

journal = "Microbial Cell",

issn = "2311-2638",

publisher = "Shared Science Publishers OG",

number = "7",

}

TY - JOUR

T1 - Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

AU - Dijck, Patrick Van

AU - Sjollema, Jelmer

AU - Cammue, Bruno P.A.

AU - Lagrou, Katrien

AU - Berman, Judith

AU - d'Enfert, Christophe

AU - Andes, David R.

AU - Arendrup, Maiken C.

AU - Brakhage, Axel A.

AU - Calderone, Richard

AU - Cantón, Emilia

AU - Coenye, Tom

AU - Cos, Paul

AU - Cowen, Leah E.

AU - Edgerton, Mira

AU - Espinel-Ingroff, Ana

AU - Filler, Scott G.

AU - Ghannoum, Mahmoud

AU - Gow, Neil A R

AU - Haas, Hubertus

AU - Jabra-Rizk, Mary Ann

AU - Johnson, Elizabeth M.

AU - Lockhart, Shawn R.

AU - López-Ribot, José L.

AU - Maertens, Johan

AU - Munro, Carol A.

AU - Nett, Jeniel E.

AU - Nobile, Clarissa J.

AU - Pfaller, Michael A.

AU - Ramage, Gordon

AU - Sanglard, Dominique

AU - Sanguinetti, Maurizio

AU - Spriet, Isabel

AU - Verweij, Paul E.

AU - Warris, Adilia

AU - Wauters, Joost

AU - Yeaman, Michael R.

AU - Zaat, Sebastian A.J.

AU - Thevissen, Karin

N1 - KT acknowledges receipt of a mandate of Industrial Research Fund (IOFm/05/022). JB acknowledges funding from the European Research Council Advanced Award 3400867/RAPLODAPT and the Israel Science Foundation grant # 314/13 (www.isf.il). NG acknowledges the Wellcome Trust and MRC for funding. CD acknowledges funding from the Agence Nationale de Recherche (ANR-10-LABX-62-IBEID). CJN acknowledges funding from the National Institutes of Health R35GM124594 and R21AI125801. AW is supported by the Wellcome Trust Strategic Award (grant 097377), the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen MaCA: outside this study MaCA has received personal speaker’s honoraria the past five years from Astellas, Basilea, Gilead, MSD, Pfizer, T2Candida, and Novartis. She has received research grants and contract work paid to the Statens Serum Institute from Astellas, Basilea, Gilead, MSD, NovaBiotics, Pfizer, T2Biosystems, F2G, Cidara, and Amplyx. CAM acknowledges the Wellcome Trust and the MRC MR/N006364/1. PVD, TC and KT acknowledge the FWO research community: Biology and ecology of bacterial and fungal biofilms in humans (FWO WO.009.16N). AAB acknowledges the Deutsche Forschungsgemeinschaft – CRC FungiNet.

PY - 2018/7

Y1 - 2018/7

N2 - Unlike superficial fungal infections of the skin and nails, which are the most common fungal diseases in humans, invasive fungal infections carry high morbidity and mortality, particularly those associated with biofilm formation on indwelling medical devices. Therapeutic management of these complex diseases is often complicated by the rise in resistance to the commonly used antifungal agents. Therefore, the availability of accurate susceptibility testing methods for determining antifungal resistance, as well as discovery of novel antifungal and antibiofilm agents, are key priorities in medical mycology research. To direct advancements in this field, here we present an overview of the methods currently available for determining (i) the susceptibility or resistance of fungal isolates or biofilms to antifungal or antibiofilm compounds and compound combinations; (ii) the in vivo efficacy of antifungal and antibiofilm compounds and compound combinations; and (iii) the in vitro and in vivo performance of anti-infective coatings and materials to prevent fungal biofilm-based infections.

AB - Unlike superficial fungal infections of the skin and nails, which are the most common fungal diseases in humans, invasive fungal infections carry high morbidity and mortality, particularly those associated with biofilm formation on indwelling medical devices. Therapeutic management of these complex diseases is often complicated by the rise in resistance to the commonly used antifungal agents. Therefore, the availability of accurate susceptibility testing methods for determining antifungal resistance, as well as discovery of novel antifungal and antibiofilm agents, are key priorities in medical mycology research. To direct advancements in this field, here we present an overview of the methods currently available for determining (i) the susceptibility or resistance of fungal isolates or biofilms to antifungal or antibiofilm compounds and compound combinations; (ii) the in vivo efficacy of antifungal and antibiofilm compounds and compound combinations; and (iii) the in vitro and in vivo performance of anti-infective coatings and materials to prevent fungal biofilm-based infections.

KW - antifungal susceptibility testing

KW - biofilm inhibition

KW - biofilm eradication

KW - antibiofilm material coating

KW - in vivo models

U2 - 10.15698/mic2018.07.638

DO - 10.15698/mic2018.07.638

M3 - Review article

C2 - 29992128

SN - 2311-2638

VL - 5

SP - 300

EP - 326

JO - Microbial Cell

JF - Microbial Cell

IS - 7

ER -

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this